Value through Innovation21 October 2014

Boehringer Ingelheim Group of companies

2013 was not an easy year for Boehringer Ingelheim. The fact that our growth was weaker by comparison with previous years was the result of an increasingly difficult market environment – in Europe, for example, but also in the USA and Japan.

    Financial Highlights

    Boehringer Ingelheim group of companies
     
    2013  2012 Change
    Net sales
    14,065 14,691 - 4 %
    Net sales by region
       
    Europe
    30 % 29 %
    Americas
    46 % 47 %  
    Asia, Australasia, Africa
    24 % 24 %  
    by business
         
    Prescription Medicines 77 % 78 %  
    Consumer Health Care 11 % 10 %  
    Animal Health 8 % 7 %  
    Biopharmaceuticals 3 % 4 %  
    Industrial Customers and other sales 1 % 1 %  
           
    Research and Development
    2,743 2,795  - 2 %
    Personnel costs
    4,071 4,024 + 1 %
    Average number of employees
    47,492 46,228 + 3 %
    Operating income
    2,114 1,853 + 14 %
    Operating income as % of net sales
    15.0 % 12.6 %  
    Income after taxes
    1,324 1,237 + 7 %
    Income after taxes as % of net sales
    9.4 % 8.4 %  
    Shareholders' equity
    7,122 6,178 + 15 %
    Return on shareholders' equity
    21.4 % 16.6 %  
    Cash Flow
    2,129 2,225 - 4 %
    Investments in tangible assets
    558 562 - 1 %
    Depreciation of tangible assets
    640 793 - 19 %


    Amounts in millions of EUR, unless otherwise indicated